| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2003PNAS..100.6370H |
| P356 | DOI | 10.1073/PNAS.1237107100 |
| P932 | PMC publication ID | 164453 |
| P698 | PubMed publication ID | 12750461 |
| P5875 | ResearchGate publication ID | 10757597 |
| P2093 | author name string | Michio Sato | |
| Kazuki Sato | |||
| Minako Hoshi | |||
| Akihiko Noguchi | |||
| Kaori Yasutake | |||
| Shinichiro Matsumoto | |||
| Natsuko Yoshida | |||
| P2860 | cites work | Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. | Q48622377 |
| Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. | Q48673331 | ||
| Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay | Q48917972 | ||
| Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease | Q48940326 | ||
| Soluble multimeric Alzheimer beta(1-40) pre-amyloid complexes in dilute solution. | Q53210234 | ||
| Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. | Q53218877 | ||
| Atomic force microscopy imaging of double stranded DNA and RNA | Q68001936 | ||
| Beta-amyloid deposition and paired helical filament formation: which histopathological feature is more significant in Alzheimer's disease? | Q69551719 | ||
| Arrest of beta-amyloid fibril formation by a pentapeptide ligand | Q71058625 | ||
| Solid-like behaviour of unsheared sickle haemoglobin gels and the effects of shear | Q71410203 | ||
| Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A | Q71918546 | ||
| Observation of metastable Abeta amyloid protofibrils by atomic force microscopy | Q73431442 | ||
| Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide | Q73514544 | ||
| A molecular mechanism for the effect of lithium on development | Q24629067 | ||
| Improvements in epoxy resin embedding methods | Q24656558 | ||
| Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease | Q24670696 | ||
| Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo | Q28131779 | ||
| Alzheimer's disease: genes, proteins, and therapy | Q28131806 | ||
| Glycogen synthase kinase-3: properties, functions, and regulation | Q28212200 | ||
| Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity | Q28378569 | ||
| Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 | ||
| Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment | Q29547294 | ||
| Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins | Q29547593 | ||
| Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein | Q29547803 | ||
| Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases | Q29616535 | ||
| Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells | Q29618245 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease | Q32028060 | ||
| A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease | Q33292093 | ||
| Anti-bipolar therapy: mechanism of action of lithium | Q33596950 | ||
| Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? | Q34183637 | ||
| Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death | Q35052504 | ||
| Intraneuronal Abeta42 accumulation in human brain. | Q35793325 | ||
| Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. | Q35969894 | ||
| Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons | Q36324215 | ||
| Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain | Q37672243 | ||
| On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants | Q37731494 | ||
| Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. | Q41412181 | ||
| Production of the Alzheimer amyloid beta protein by normal proteolytic processing | Q41599298 | ||
| Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution | Q42153291 | ||
| Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. | Q42447316 | ||
| Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state | Q44689258 | ||
| Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations | Q46204569 | ||
| A critical role for amino-terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion | Q46347783 | ||
| A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease | Q47583762 | ||
| Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy | Q47852610 | ||
| Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. | Q48093908 | ||
| Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration | Q48163930 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toxic encephalopathy | Q7830379 |
| neurotoxicity | Q3338704 | ||
| P304 | page(s) | 6370-6375 | |
| P577 | publication date | 2003-05-15 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta | |
| P478 | volume | 100 |
| Q36628151 | A century-old debate on protein aggregation and neurodegeneration enters the clinic |
| Q37635631 | ABCA1 Deficiency Affects Basal Cognitive Deficits and Dendritic Density in Mice. |
| Q46380915 | Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. |
| Q90620606 | Acetylation of Aβ42 at Lysine 16 Disrupts Amyloid Formation |
| Q37108156 | Advances on the understanding of the origins of synaptic pathology in AD. |
| Q30448740 | Aggregation and fibril morphology of the Arctic mutation of Alzheimer's Aβ peptide by CD, TEM, STEM and in situ AFM |
| Q50731159 | Aggregation of partially unfolded Myosin subfragment-1 into spherical oligomers with amyloid-like dye-binding properties. |
| Q40678915 | AlphaB-crystallin, a small heat-shock protein, prevents the amyloid fibril growth of an amyloid beta-peptide and beta2-microglobulin |
| Q64088896 | Alzheimer Aβ Assemblies Accumulate in Excitatory Neurons upon Proteasome Inhibition and Kill Nearby NAKα3 Neurons by Secretion |
| Q35695716 | Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials |
| Q35126030 | Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers |
| Q37636545 | Alzheimer's disease: synaptic dysfunction and Abeta |
| Q34849544 | Amyloid beta-protein assembly and Alzheimer disease |
| Q41402121 | Amyloid nanospheres from polyglutamine rich peptides: assemblage through an intermolecular salt bridge interaction |
| Q36855702 | Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease |
| Q35586308 | Amyloid polymorphism: structural basis and neurobiological relevance |
| Q37690332 | Amyloid β-protein oligomers and Alzheimer's disease |
| Q40404080 | Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay |
| Q42976903 | Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. |
| Q28748498 | Amyloid-β Oligomer Specificity Mediated by the IgM Isotype – Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies |
| Q96438340 | Amyloid-β Oligomerization Monitored by Single-Molecule Stepwise Photobleaching |
| Q38506872 | Amyloidogenesis of type III-dependent harpins from plant pathogenic bacteria |
| Q24653554 | Amyloids: friend or foe? |
| Q90007223 | An RNA aptamer with potent affinity for a toxic dimer of amyloid β42 has potential utility for histochemical studies of Alzheimer's disease |
| Q30155916 | Analysis of the stabilities of hexameric amyloid-β(1-42) models using discrete molecular dynamics simulations |
| Q44824206 | Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy |
| Q35590968 | Anti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment |
| Q38807908 | Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy. |
| Q30365652 | Antiparallel triple-strand architecture for prefibrillar Aβ42 oligomers |
| Q90732521 | Apolipoprotein E particle size is increased in Alzheimer's disease |
| Q42084058 | Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon |
| Q28743838 | Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease |
| Q38589816 | Beta Amyloid Hallmarks: From Intrinsically Disordered Proteins to Alzheimer's Disease |
| Q37420497 | Beta amyloid peptide: from different aggregation forms to the activation of different biochemical pathways. |
| Q30351145 | Beta-amyloid protein structure determines the nature of cytokine release from rat microglia. |
| Q45249980 | Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. |
| Q30156038 | Beta‐barrel models of soluble amyloid beta oligomers and annular protofibrils |
| Q28393352 | Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status |
| Q42093156 | Can size alone explain some of the differences in toxicity between beta-amyloid oligomers and fibrils? |
| Q45424586 | Cetyltrimethylammonium bromide-induced unordered aggregation of coat protein of tobacco mosaic virus at room temperature |
| Q35144769 | Characterization of oligomer formation of amyloid-beta peptide using a split-luciferase complementation assay |
| Q47833634 | Characterization of the spherical intermediates and fibril formation of hCT in HEPES solution using solid-state 13C-NMR and transmission electron microscopy |
| Q60693600 | Choroid Plexus Megalin Is Involved in Neuroprotection by Serum Insulin-Like Growth Factor I |
| Q51357613 | Citrullination and deamidation affect aggregation properties of amyloid β-proteins. |
| Q34800214 | Combinatorial Tau pseudophosphorylation: markedly different regulatory effects on microtubule assembly and dynamic instability than the sum of the individual parts |
| Q38240609 | Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease |
| Q36098093 | Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity |
| Q39617658 | Copper(II) complexes of hybrid hydroxyquinoline-thiosemicarbazone ligands: GSK3β inhibition due to intracellular delivery of copper. |
| Q57956891 | Copper(ii) and zinc(ii) dependent effects on Aβ42 aggregation: a CD, Th-T and SFM study |
| Q59203928 | Curcumin-like compounds designed to modify amyloid beta peptide aggregation patterns |
| Q40337352 | Cytokine production by a human microglial cell line: effects of beta-amyloid and alpha-melanocyte-stimulating hormone |
| Q36729485 | Cytoskeletal transport in the aging brain: focus on the cholinergic system |
| Q41894199 | Detecting amyloid-beta aggregation with fiber-based fluorescence correlation spectroscopy |
| Q36983231 | Development of photocrosslinked sialic acid containing polymers for use in Abeta toxicity attenuation |
| Q38841150 | Dicyanovinyl-substituted J147 analogue inhibits oligomerization and fibrillation of β-amyloid peptides and protects neuronal cells from β-amyloid-induced cytotoxicity. |
| Q33946695 | Differences between amyloid-β aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease. |
| Q28680809 | Disease modifying therapies for Alzheimer's disease targeting Aβ oligomers: implications for therapeutic mechanisms |
| Q34685007 | Distinct effects of Zn2+, Cu2+, Fe3+, and Al3+ on amyloid-beta stability, oligomerization, and aggregation: amyloid-beta destabilization promotes annular protofibril formation |
| Q40485526 | Does the cytotoxic effect of transient amyloid oligomers from common equine lysozyme in vitro imply innate amyloid toxicity? |
| Q26749755 | Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT |
| Q34353013 | Early events in insulin fibrillization studied by time-lapse atomic force microscopy |
| Q33649803 | Effect of metals on kinetic pathways of amyloid-β aggregation |
| Q48505432 | Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture |
| Q40271638 | Endogenous overproduction of beta-amyloid induces tau hyperphosphorylation and decreases the solubility of tau in N2a cells |
| Q37302801 | Endothelial nitric oxide deficiency promotes Alzheimer's disease pathology |
| Q45005831 | Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution |
| Q37280507 | Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy |
| Q46866171 | Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid. |
| Q37238270 | Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments |
| Q38027946 | Exploiting amyloid: how and why bacteria use cross-β fibrils |
| Q30481429 | Exploring the mechanism of beta-amyloid toxicity attenuation by multivalent sialic acid polymers through the use of mathematical models |
| Q24633896 | Expression and purification of 15N- and 13C-isotope labeled 40-residue human Alzheimer's β-amyloid peptide for NMR-based structural analysis |
| Q37173085 | Expression and purification of amyloid-beta peptides from Escherichia coli |
| Q28741744 | Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse |
| Q37409748 | FcγRIIb-SHIP2 axis links Aβ to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model. |
| Q33673470 | Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation |
| Q48182955 | Fibrillogenic oligomers of human cystatin C are formed by propagated domain swapping |
| Q34557414 | Formation of Toxic Amyloid Fibrils by Amyloid β-Protein on Ganglioside Clusters |
| Q21202837 | Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin |
| Q37983824 | Formation of the 42-mer Amyloid β Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer's Disease |
| Q35001040 | GSK-3 in Neurodegenerative Diseases. |
| Q27642879 | GSK-3-selective inhibitors derived from Tyrian purple indirubins |
| Q34081720 | GSK3β is involved in the relief of mitochondria pausing in a Tau-dependent manner |
| Q39657177 | Ganglioside‐mediated aggregation of amyloid β‐proteins (Aβ): comparison between Aβ‐(1–42) and Aβ‐(1–40) |
| Q37662445 | Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. |
| Q53284202 | High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide. |
| Q34553059 | Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits |
| Q35103820 | In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors |
| Q33231356 | Interaction of huntingtin fragments with brain membranes--clues to early dysfunction in Huntington's disease |
| Q38121070 | Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. |
| Q37432185 | Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. |
| Q30434894 | Kinetic study of beta-amyloid residue accessibility using reductive alkylation and mass spectrometry |
| Q28732085 | Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation |
| Q47289038 | Large size fibrillar bundles of the Alzheimer amyloid beta-protein. |
| Q41862498 | Lithium-induced neuroprotection is associated with epigenetic modification of specific BDNF gene promoter and altered expression of apoptotic-regulatory proteins |
| Q42425724 | Measurement of the attachment and assembly of small amyloid-β oligomers on live cell membranes at physiological concentrations using single-molecule tools. |
| Q37353196 | Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet |
| Q33536103 | Mechanisms of enzymatic degradation of amyloid Beta microfibrils generating nanofilaments and nanospheres related to cytotoxicity |
| Q37630546 | Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease |
| Q37225388 | Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers |
| Q45271567 | Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide |
| Q95943213 | Molecular interactions between monoclonal oligomer-specific antibody 5E3 and its amyloid beta cognates |
| Q43112389 | Molecular structure of amyloid fibrils formed by residues 127 to 147 of the human prion protein. |
| Q33303421 | Molecules that target beta-amyloid |
| Q37690524 | Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis |
| Q35199200 | Myelin basic protein binds to and inhibits the fibrillar assembly of Abeta42 in vitro |
| Q34046583 | Mysterious oligomerization of the amyloidogenic proteins |
| Q28572007 | Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assembly. |
| Q53331979 | Negatively charged gold nanoparticles inhibit Alzheimer's amyloid-β fibrillization, induce fibril dissociation, and mitigate neurotoxicity. |
| Q37408544 | Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease |
| Q48569616 | Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. |
| Q36687844 | Neurogenesis and neuroenhancement in the pathophysiology and treatment of bipolar disorder |
| Q36863389 | Novel therapeutic strategies for the treatment of protein-misfolding diseases |
| Q80940333 | Overexpression of GSK3betaS9A resulted in tau hyperphosphorylation and morphology reminiscent of pretangle-like neurons in the brain of PDGSK3beta transgenic mice |
| Q42021752 | Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? |
| Q28483828 | Peptide nanovesicles formed by the self-assembly of branched amphiphilic peptides |
| Q64950267 | Pharmacological Potential of Cilostazol for Alzheimer's Disease. |
| Q59203945 | Photo-inhibition of Aβ fibrillation mediated by a newly designed fluorinated oxadiazole |
| Q34476355 | Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. |
| Q27974527 | Plasmodium falciparum merozoite surface protein 3: oligomerization, self-assembly, and heme complex formation |
| Q34299359 | Polymorphic C-terminal β-Sheet Interactions Determine the Formation of Fibril or Amyloid β-derived Diffusible Ligand-like Globulomer for the Alzheimer Aβ42 Dodecamer |
| Q34059772 | Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape |
| Q37454220 | Polymorphism of fibrillar structures depending on the size of assembled Aβ17-42 peptides |
| Q48456315 | Prefibrillar amyloid aggregates could be generic toxins in higher organisms. |
| Q48169675 | Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research |
| Q89052841 | Preparation of Pure Populations of Amyloid β-Protein Oligomers of Defined Size |
| Q46201444 | Preparation of amyloid beta-protein for structural and functional studies |
| Q49744153 | Preparation of stable amyloid β-protein oligomers of defined assembly order |
| Q36876447 | Present and prospective clinical therapeutic regimens for Alzheimer's disease |
| Q35534356 | Probing the efficacy of peptide-based inhibitors against acid- and zinc-promoted oligomerization of amyloid-β peptide via single-oligomer spectroscopy |
| Q42105214 | Proline Residues as Switches in Conformational Changes Leading to Amyloid Fibril Formation |
| Q43187852 | Protein folding and misfolding on surfaces. |
| Q53372069 | Protofibril formation of amyloid beta-protein at low pH via a non-cooperative elongation mechanism. |
| Q53459283 | Puerarin alleviates cognitive impairment and oxidative stress in APP/PS1 transgenic mice. |
| Q37751240 | Quantitative analysis of MAP-mediated regulation of microtubule dynamic instability in vitro focus on Tau. |
| Q37187966 | Reassessing the amyloid cascade hypothesis of Alzheimer's disease |
| Q39145449 | Recent Progress in Alzheimer's Disease Research, Part 1: Pathology |
| Q46943581 | Republished: the role of amyloid β in the pathogenesis of Alzheimer's disease |
| Q37517959 | Review of lithium effects on brain and blood |
| Q30443312 | Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Abeta fibril formation pathway |
| Q37961445 | Selective molecular recognition in amyloid growth and transmission and cross-species barriers |
| Q40108904 | Sensitive ELISA detection of amyloid-beta protofibrils in biological samples |
| Q39947061 | Sequestration of copper from beta-amyloid promotes selective lysis by cyclen-hybrid cleavage agents |
| Q24656147 | Signaling effect of amyloid-beta(42) on the processing of AbetaPP |
| Q57186606 | Similar toxicity of the oligomeric molten globule state and the prefibrillar oligomers |
| Q43477001 | Size and morphology of toxic oligomers of amyloidogenic proteins: a case study of human stefin B. |
| Q33742590 | Small Molecule Microarrays Enable the Discovery of Compounds That Bind the Alzheimer’s Aβ Peptide and Reduce its Cytotoxicity |
| Q41443925 | Solution NMR studies of recombinant Aβ(1-42): from the presence of a micellar entity to residual β-sheet structure in the soluble species. |
| Q57374159 | Specific binding of amyloid-beta-protein to IMR-32 neuroblastoma cell membrane |
| Q38131699 | Statistical mechanical treatments of protein amyloid formation |
| Q42198100 | Structural Insight into an Alzheimer's Brain-Derived Spherical Assembly of Amyloid β by Solid-State NMR |
| Q30484255 | Structural classification of toxic amyloid oligomers |
| Q36967253 | Structural insights into Aβ42 oligomers using site-directed spin labeling |
| Q34574518 | Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins |
| Q33716773 | Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders |
| Q36749672 | Studying polyglutamine aggregation in Caenorhabditis elegans using an analytical ultracentrifuge equipped with fluorescence detection. |
| Q40842685 | Successive Stages of Amyloid-β Self-Assembly Characterized by Solid-State Nuclear Magnetic Resonance with Dynamic Nuclear Polarization |
| Q42618236 | Synthesis and Purification of Highly Hydrophobic Peptides Derived from the C-Terminus of Amyloid β-Protein |
| Q26822002 | Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics |
| Q39447017 | The Mechanism Underlying Amyloid Polymorphism is Opened for Alzheimer's Disease Amyloid-β Peptide |
| Q26768487 | The Therapeutic Potential of Rosemary (Rosmarinus officinalis) Diterpenes for Alzheimer's Disease |
| Q37675721 | The biochemical study on the etiology of Alzheimer's disease |
| Q24294387 | The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway |
| Q35194588 | The elusive nature and diagnostics of misfolded Aβ oligomers |
| Q44853344 | The formation of straight and twisted filaments from short tau peptides |
| Q38520167 | The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration |
| Q36872887 | The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease |
| Q35103813 | The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways |
| Q35209026 | The peculiar role of the A2V mutation in amyloid-β (Aβ) 1-42 molecular assembly |
| Q36063543 | The role of caspase cleavage of tau in Alzheimer disease neuropathology |
| Q37979641 | The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes |
| Q33621850 | The turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease |
| Q51026158 | The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease. |
| Q37550818 | Therapeutic strategies for tau mediated neurodegeneration |
| Q39137730 | Thermodynamically stable amyloid-β monomers have much lower membrane affinity than the small oligomers. |
| Q92723849 | Three Structural Features of Functional Food Components and Herbal Medicine with Amyloid β42 Anti-Aggregation Properties |
| Q36711191 | Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation |
| Q50740397 | Transglutaminases Derived from Astrocytes Accelerate Amyloid β Aggregation. |
| Q35035648 | Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease |
| Q34719716 | Two distinct amyloid beta-protein (Abeta) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses |
| Q36238193 | Two-step mechanism of membrane disruption by Aβ through membrane fragmentation and pore formation |
| Q38101982 | Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes |
| Q36836607 | Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. |
| Q33778710 | Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis |
| Q36016964 | Zn2+-Aβ40 complexes form metastable quasi-spherical oligomers that are cytotoxic to cultured hippocampal neurons |
| Q34505802 | αB-Crystallin inhibits the cell toxicity associated with amyloid fibril formation by κ-casein and the amyloid-β peptide |
| Q30498160 | β-Amyloid impairs axonal BDNF retrograde trafficking |
Search more.